Exelixis, Inc. (NASDAQ:EXEL) authorized repurchasing up to an additional $500 million of the company’s common stock before ...

Cancer drug specialist Exelixis (NASDAQ: EXEL) was quite the stock market star on Friday. Following news that it's making a ...

The American quant hedge fund Renaissance Technologies is known for using statistical and mathematical tools to drive its ...

Exelixis’ next-generation tyrosine kinase inhibitor zanzalintinib is being tested for colorectal cancer, renal cell carcinoma ...

Newly published detailed clinical trial data show why Exelixis abandoned a plan to seek an FDA approval for a combination of ...

Exelixis, Inc. (Nasdaq: EXEL) today announced that the company’s Board of Directors has authorized the repurchase of up to an additional $500 million of the company’s common stock before December 31, ...

Exelixis (EXEL) announced final results from the phase 3 CheckMate -9ER pivotal trial evaluating Cabometyx in combination with Opdivo versus ...

(RTTNews) - Exelixis, Inc. (EXEL) Thursday announced that its Board of Directors has authorized an additional $500 million stock repurchase program, set to run through December 31. The company ...

In a report released today, Peter Lawson from Barclays maintained a Hold rating on Exelixis (EXEL – Research Report), with a price target of ...

Exelixis (NASDAQ:EXEL – Get Free Report) was upgraded by equities research analysts at StockNews.com from a “buy” rating to a “strong-buy” rating in a research note issued on Wednesday.